96-well light gray 1/2 area microplate. Half-area plates utilize the same well spacing as a regular 96-well plate, but contain wells with half the diameter of a typical 96-well plate. This enables miniaturization to lower assay volumes while retaining ease-of-pipetting. Light gray plates can help minimize cross-talk while maintaining high signal in luminescent and Alpha assays.
true false
PerkinElmer's ½ AreaPlate offers same well depth at half the size to help you miniaturize your assay, designed to utilize cost reduction advantages without going to a 384-well format.
PerkinElmer is proud to have designed a light gray microplate which addresses unique challenges of sample screening. Our uniquely engineered 384 well and 1536 well light gray AlphaPlate microplates combine the best features of white microplates (excellent signal-to-background) and black microplates (decreased well-to-well crosstalk) for superior assay window and sensitivity in comparison to any other plate for luminescence assays. Our AlphaPlates are designed for a variety of technologies for luminescence based assays, but are specifically designed for use with PerkinElmer’s AlphaLISA and AlphaScreen technologies.
It’s important to choose the correct microplate prior to your screening project. By choosing the incorrect microplate, challenges such as missed data points, sample re-screening, missed project timelines and ultimately higher costs can be incurred.
| Automation Compatible | Yes |
|---|---|
| Coating Treatment | Untreated |
| Color | Gray |
| Detection Method | Luminescence, Alpha |
| Material | Polystyrene |
| Product Brand Name | ½ AreaPlate |
| Shipping Condition | Ambient |
| Sterile | No |
| Unit Size | 2 x 25 plates |
Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / antibody fragment to two or more binding sites to help with the treatment of complex diseases.
As more bsAbs are produced as therapeutics, fast and accurate methods for functionally evaluating and characterizing the stability of these antibodies are necessary during both discovery and development stages, as well as during formulation and quality analysis.
In this application note, we demonstrate how AlphaLISA® assay technology with the EnVision® multimode plate reader can be used for bispecific antibody detection, through an example application to characterize the binding and specificity of a mouse bispecific antibody targeting mouse TIGIT and mouse PD-L1.
You will find out:
When Non-alcoholic fatty liver disease (NAFLD) progresses to nonalcoholic steatohepatitis (NASH), with inflammation and damage to liver cells it can cause fibrosis, cirrhosis and liver failure or cancer. Despite the prevalence of NAFLD and NASH rising, their remains no approved treatments. But studies show that fat and scar tissue can leave the liver, suggesting that they are reversible.
This brochure guides you through complete solutions to support your NASH research efforts.
TNFα (human) AlphaLISA Detection Kit, 500 Assay Points
List Price : USD1905.0
List Price : USD70.0
